Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454649
Status:
COMPLETED
Last Update Posted:
2012-04-04
First Post:
2007-03-29
Brief Title:
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patients With Advanced Solid Tumor
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations Of PaclitaxelCarboplatin Weekly Paclitaxel Docetaxel Capecitabine GemcitabineCisplatin and PemetrexedCisplatin In Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None